Perimeter Medical Imaging AI Provides Corporate Update

Perimeter Medical Imaging

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today provided a corporate update on the progress made to date to grow its commercial organization.

Under the leadership of Steve Sapot, Perimeter’s Chief Commercial Officer, the Company continues to build the infrastructure to support and expand its sales and marketing team, including the addition of the initial four key market development managers tasked with launching Perimeter’s novel S-Series OCT medical imaging technology in the U.S. market.

Steve Sapot commented, “We continue to attract top-tier sales professionals to our roster, including the addition of four highly accomplished market development managers, who bring experience from leading medtech companies including Medtronic, BD, Stanley Healthcare, and Sonosite. These core team members cover key regions in the U.S. where we have strategically identified the leading healthcare institutions that could represent the ideal early adopters of our innovative, ‘real-time’ OCT imaging technology. Our sales and marketing team is passionate about delivering Perimeter’s technology to leading U.S. physicians, with the ultimate goal of improving patient outcomes and lowering healthcare costs.”

Jeremy Sobotta, Perimeter’s Chief Executive Officer stated, “Our Chief Commercial Officer along with these first four Perimeter market development managers have impressive track records in similar ‘go-to-market’ strategies with our target customers. We consider the high caliber of talent that we have added to our sales team as another point of validation of Perimeter’s novel imaging technology and its potential to address a significant unmet medical need in the OR.”

Mr. Sobotta added, “In addition to the ongoing expansion of our sales team, our medical affairs and marketing teams have made significant progress towards establishing the foundational groundwork to support our commercial growth plans. Under the leadership of Dr. Sarah Butler, Perimeter’s VP, Clinical & Medical Affairs, we continue to execute on the clinical education strategies and activities with the aim of ensuring our customers’ success with our technology.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version